Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma (Cardiocare)

Azienda Ospedaliera Città della Salute e della Scienza di Torino

Status: Completed

Conditions: Hodgkin Lymphoma; Lymphoma, Non-Hodgkin; Toxicity, Cardiac

Study type: Observational

Funder types: Other

Identifiers

NCT03480087

Cardiocare

Details and patient eligibility

About

Treatments-related cardiotoxicity is a critical issue in long term lymphoma survivors, particularly at young age, and its early identification is important to prevent clinically relevant cardiac events. Complete echocardiographic assessment including 2-dimension global longitudinal strain (2D-GLS), seems to be an effective tools in detecting preclinical systolic changes to the cardiac function even when the ejection fraction is preserved. The aim of Cardiocare study is to investigate early detection of subclinical chemo and radiation-induced changes in left ventricular function using 2D-GLS.

Enrollment: 118 patients

Sex: All

Ages: 19 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >18 years
• Diagnosis of Hodgkin Disease (HD) or Primary Mediastinal B-cell lymphoma (PMBCL) or diffuse large B-cell lymphoma (DLBCL)
• Disease requiring treatment with anthracycline containing regimen only (cohort A) or anthracycline containing regimen followed by mediastinal radiotherapy (cohort B)
• Written informed consent

Exclusion criteria

• Age > 70 years
• Unable to perform anthracyline containing regimen
• Previous treatment with mediastinal radiotherapy
• Kidney failure (defined as creatinine x2 UNL) or liver failure (defined as AST and ALT x2 UNL)
• ECOG PS > 2
• Echocardiographic acoustic windows not suitable for strain evaluation
• Any other conditions or situations preventing patients to sign informed consent

Trial design

118 participants in 2 patient groups

Chemotherapy alone

Description:

Patient treated with anthracycline containing chemotherapy

Chemotherapy plus radiotherapy

Description:

Patient treated with anthracycline containing chemotherapy followed by mediastinal radiotherapy